Chemomab Therapeutics Ltd. (CMMB)

Chemomab Therapeutics Analyst Ratings

• Total Analysts: 2
• Consensus Rating: Strong Buy
• Price Target: $26.50
• Upside: +681.71%

Ratings History

Filter results

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jeff Jones Oppenheimer	Oppenheimer	Buy Maintains $10 → $25	Buy	Maintains	$10 → $25	+637.46%	Aug 27, 2025
Jeff Jones Oppenheimer	Oppenheimer	Buy Maintains $44 → $40	Buy	Maintains	$44 → $40	+1,079.94%	May 16, 2025
Michael Okunewitch Maxim Group	Maxim Group	Strong Buy Maintains $16 → $28	Strong Buy	Maintains	$16 → $28	+725.96%	Feb 20, 2025
Jeff Jones Oppenheimer	Oppenheimer	Buy Reiterates $52 → $44	Buy	Reiterates	$52 → $44	+1,197.94%	Nov 15, 2024
Michael Okunewitch Maxim Group	Maxim Group	Strong Buy Initiates $16	Strong Buy	Initiates	$16	+371.98%	May 13, 2024
Jeff Jones Oppenheimer	Oppenheimer	Hold → Buy Upgrades $24	Hold → Buy	Upgrades	$24	+607.96%	May 6, 2024
Jeff Jones Oppenheimer	Oppenheimer	Hold Maintains n/a	Hold	Maintains	n/a	n/a	Mar 8, 2024
Dylan Dupuis Roth MKM	Roth MKM	Strong Buy Initiates $28	Strong Buy	Initiates	$28	+725.96%	Dec 19, 2023
Dylan Dupuis Roth MKM	Roth MKM	Strong Buy Initiates $28	Strong Buy	Initiates	$28	+725.96%	Oct 6, 2023
Jeff Jones Oppenheimer	Oppenheimer	Buy → Hold Downgrades n/a	Buy → Hold	Downgrades	n/a	n/a	Jun 7, 2023
Jeff Jones Oppenheimer	Oppenheimer	Buy Maintains $48 → $28	Buy	Maintains	$48 → $28	+725.96%	Apr 18, 2023
Jeff Jones Oppenheimer	Oppenheimer	Buy Maintains $120 → $80	Buy	Maintains	$120 → $80	+2,259.88%	Mar 10, 2022
Nathan Weinstein Aegis Capital	Aegis Capital	Strong Buy Initiates $120	Strong Buy	Initiates	$120	+3,439.82%	Dec 7, 2021
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Buy Initiates $180	Buy	Initiates	$180	+5,209.73%	May 26, 2021
Jeff Jones Oppenheimer	Oppenheimer	Buy Initiates $168	Buy	Initiates	$168	+4,855.75%	May 7, 2021